DURECT Provides An Update To The Memryte(TM) Program Under Development By Voyager Pharmaceutical Corp.

DURECT Provides An Update To The Memryte(TM) Program Under Development By Voyager Pharmaceutical Corp.: "DURECT Corporation (Nasdaq: DRRX) announced today that Voyager Pharmaceutical has informed DURECT that Voyager is ending its Phase III clinical trials for Memryte(TM) for the treatment of Alzheimer's Disease in order to get an earlier look at potential efficacy from over 600 accrued patients."